News

Akili Reports First Quarter 2024 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. “We are working expeditiously with our board of directors and our external advisors and look forwar.

05/14/2024

Why Is Akili (AKLI) Stock Up 68% Today?

Akili (NASDAQ: AKLI ) stock is rocketing higher on Tuesday after the digital medicine company provided investors with a positive corporate update. According to this update, Shionogi has canceled and forgiven $5 million in debt that Akili owed it.

04/30/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Akili, Inc. (AKLI) a buy, sell, or hold?

Akili, Inc. (AKLI) can hold. Click on Rating Page for detail.

What is Akili, Inc.'s stock price?

The price of Akili, Inc. (AKLI) is 0.437 and it was updated on 2024-05-16 13:00:50.

Is Akili, Inc. (AKLI) overvalued or undervalued?

Currently Akili, Inc. (AKLI) is in undervalued.

News

From:

To:

News
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress. “We continue to see clear demand for our innovative, digital therapeutics, particularly amidst the ongoing mental health crisis and increasing awareness of adult ADHD prevalence,” said Matt Franklin, Chief Executive Officer at Akili. “Our mid-year shift to a leaner, custom. Thu, Feb. 29, 2024
Should You Sell Your Penny Stocks? 3 Tips for When to Sell Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow individuals to purchase shares in emerging companies without a significant financial outlay. Tue, Feb. 27, 2024
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of A. Tue, Feb. 27, 2024
Why Is Akili (AKLI) Stock Up 110% Today? A little known penny stock is turning heads on Wall Street today as it surges to impressive heights. Digital health company Akili Interactive Labs (NASDAQ: AKLI ) stock is soaring after reporting a positive trial update. Mon, Feb. 26, 2024
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili's AKL-T01 (marketed as EndeavorRx® in the United States), which has previously been authorized by the U.S. Food and Drug Administration (FDA) as the world's first prescrip. Mon, Feb. 26, 2024

Transcripts

Transcipts Data
Akili, Inc. (AKLI) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Sun, Nov. 12, 2023
Akili, Inc. (AKLI) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Sun, Aug. 13, 2023
Akili, Inc. (AKLI) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Thu, May. 11, 2023
Akili, Inc. (AKLI) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Fri, Mar. 10, 2023
Akili, Inc. (AKLI) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Sun, Nov. 13, 2022

SEC Filings

SEC Filings
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 05/14/2024
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Akili, Inc. (AKLI) - 4 SEC Filings 05/06/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 04/30/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 04/23/2024
Akili, Inc. (AKLI) - 4 SEC Filings 03/12/2024
Akili, Inc. (AKLI) - DEFA14A SEC Filings 03/06/2024
Akili, Inc. (AKLI) - DEF 14A SEC Filings 03/06/2024
Akili, Inc. (AKLI) - ARS SEC Filings 03/06/2024
Akili, Inc. (AKLI) - S-8 SEC Filings 02/29/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 02/26/2024
Akili, Inc. (AKLI) - PRE 14A SEC Filings 02/23/2024
Akili, Inc. (AKLI) - 4 SEC Filings 02/23/2024
Akili, Inc. (AKLI) - 3 SEC Filings 02/23/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 02/21/2024
Akili, Inc. (AKLI) - SC 13G SEC Filings 02/12/2024
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 01/29/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 01/05/2024
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 12/20/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 12/18/2023
Akili, Inc. (AKLI) - 4 SEC Filings 12/08/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 11/09/2023
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 11/09/2023
Akili, Inc. (AKLI) - 4 SEC Filings 11/06/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 10/27/2023
Akili, Inc. (AKLI) - 4 SEC Filings 10/13/2023
Akili, Inc. (AKLI) - SC 13D/A SEC Filings 10/06/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 10/06/2023
Akili, Inc. (AKLI) - 4 SEC Filings 10/06/2023
Akili, Inc. (AKLI) - EFFECT SEC Filings 10/02/2023
Akili, Inc. (AKLI) - POS AM SEC Filings 09/27/2023
Akili, Inc. (AKLI) - 4 SEC Filings 09/14/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 09/13/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 09/13/2023
Akili, Inc. (AKLI) - POS AM SEC Filings 09/05/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 08/10/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 08/10/2023
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 08/10/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 06/07/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 06/07/2023
Akili, Inc. (AKLI) - 8-K/A - Current report SEC Filings 05/12/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 05/12/2023
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 05/12/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 05/11/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 05/11/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 05/04/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 05/04/2023
Akili, Inc. (AKLI) - 4 SEC Filings 05/04/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 05/03/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 05/03/2023
Akili, Inc. (AKLI) - EFFECT SEC Filings 03/27/2023
Akili, Inc. (AKLI) - DEFA14A SEC Filings 03/22/2023
Akili, Inc. (AKLI) - DEF 14A SEC Filings 03/22/2023
Akili, Inc. (AKLI) - ARS SEC Filings 03/22/2023
Akili, Inc. (AKLI) - POS AM SEC Filings 03/21/2023
Akili, Inc. (AKLI) - 4 SEC Filings 03/14/2023
Akili, Inc. (AKLI) - 10-K - Current report SEC Filings 03/09/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 03/07/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 03/07/2023
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 02/14/2023
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 02/13/2023
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 02/09/2023
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 02/07/2023
Akili, Inc. (AKLI) - SC 13G SEC Filings 01/20/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 01/12/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 01/12/2023
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 01/05/2023
Akili, Inc. (AKLI) - 424B3 SEC Filings 01/05/2023
Akili, Inc. (AKLI) - 8-K/A - Current report SEC Filings 12/27/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 12/23/2022
Akili, Inc. (AKLI) - 3/A SEC Filings 12/13/2022
Akili, Inc. (AKLI) - 424B3 SEC Filings 11/14/2022
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 11/10/2022
Akili, Inc. (AKLI) - 424B3 SEC Filings 11/10/2022
Akili, Inc. (AKLI) - 4 SEC Filings 11/04/2022
Akili, Inc. (AKLI) - S-8 SEC Filings 10/27/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 10/27/2022
Akili, Inc. (AKLI) - 3 SEC Filings 10/27/2022
Akili, Inc. (AKLI) - EFFECT SEC Filings 10/18/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 10/17/2022
Akili, Inc. (AKLI) - 424B3 SEC Filings 10/17/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 10/13/2022
Akili, Inc. (AKLI) - S-1/A SEC Filings 09/30/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 09/30/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 09/27/2022
Akili, Inc. (AKLI) - S-1/A SEC Filings 09/12/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 09/12/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 09/06/2022
Akili, Inc. (AKLI) - SC 13D SEC Filings 08/30/2022
Akili, Inc. (AKLI) - SC 13G SEC Filings 08/29/2022
Akili, Inc. (AKLI) - SC 13G SEC Filings 08/26/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 08/25/2022
Akili, Inc. (AKLI) - S-1 SEC Filings 08/24/2022
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 08/23/2022
Akili, Inc. (AKLI) - SC 13D SEC Filings 08/23/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 08/23/2022
Akili, Inc. (AKLI) - 4 SEC Filings 08/23/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 08/19/2022
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 08/12/2022
Akili, Inc. (AKLI) - 425 SEC Filings 08/02/2022
Akili, Inc. (AKLI) - 425 SEC Filings 08/01/2022
Akili, Inc. (AKLI) - SEC STAFF LETTER SEC Filings 07/25/2022
Akili, Inc. (AKLI) - EFFECT SEC Filings 07/22/2022
Akili, Inc. (AKLI) - DEFM14A SEC Filings 07/21/2022
Akili, Inc. (AKLI) - 424B3 SEC Filings 07/21/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 07/19/2022
Akili, Inc. (AKLI) - S-4/A SEC Filings 07/14/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 07/14/2022
Akili, Inc. (AKLI) - 425 SEC Filings 07/11/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 07/08/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 06/30/2022
Akili, Inc. (AKLI) - S-4/A SEC Filings 06/27/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 06/27/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 06/17/2022
Akili, Inc. (AKLI) - S-4/A SEC Filings 06/10/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 06/10/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 05/25/2022
Akili, Inc. (AKLI) - 8-K/A - Current report SEC Filings 05/20/2022
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 05/16/2022
Akili, Inc. (AKLI) - S-4/A SEC Filings 05/12/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 05/12/2022
Akili, Inc. (AKLI) - 425 SEC Filings 04/28/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 04/22/2022
Akili, Inc. (AKLI) - UPLOAD SEC Filings 04/21/2022
Akili, Inc. (AKLI) - SEC STAFF LETTER SEC Filings 04/14/2022
Akili, Inc. (AKLI) - 425 SEC Filings 04/12/2022
Akili, Inc. (AKLI) - S-4/A SEC Filings 04/04/2022
Akili, Inc. (AKLI) - CORRESP SEC Filings 04/04/2022
Akili, Inc. (AKLI) - 425 SEC Filings 04/04/2022
Akili, Inc. (AKLI) - 10-K - Current report SEC Filings 03/23/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/17/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/11/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/09/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/08/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/07/2022
Akili, Inc. (AKLI) - 425 SEC Filings 03/02/2022
Akili, Inc. (AKLI) - 425 SEC Filings 02/18/2022
Akili, Inc. (AKLI) - 425 SEC Filings 02/17/2022
Akili, Inc. (AKLI) - SC 13G SEC Filings 02/15/2022
Akili, Inc. (AKLI) - S-4 SEC Filings 02/14/2022
Akili, Inc. (AKLI) - 425 SEC Filings 02/14/2022
Akili, Inc. (AKLI) - SC 13G SEC Filings 02/09/2022
Akili, Inc. (AKLI) - SC 13G SEC Filings 02/07/2022
Akili, Inc. (AKLI) - 425 SEC Filings 01/28/2022
Akili, Inc. (AKLI) - 8-K/A - Current report SEC Filings 01/27/2022
Akili, Inc. (AKLI) - 425 SEC Filings 01/27/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 01/26/2022
Akili, Inc. (AKLI) - 425 SEC Filings 01/26/2022
Akili, Inc. (AKLI) - SC 13G/A SEC Filings 01/25/2022
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 11/16/2021
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 11/15/2021
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 09/24/2021
Akili, Inc. (AKLI) - 4 SEC Filings 08/16/2021
Akili, Inc. (AKLI) - 10-Q - Quarterly Report SEC Filings 08/16/2021
Akili, Inc. (AKLI) - SC 13G SEC Filings 07/12/2021
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 07/09/2021
Akili, Inc. (AKLI) - SC 13G SEC Filings 07/07/2021
Akili, Inc. (AKLI) - 4 SEC Filings 07/07/2021
Akili, Inc. (AKLI) - 8-K - Current report SEC Filings 07/02/2021
Akili, Inc. (AKLI) - 424B4 SEC Filings 07/01/2021
Akili, Inc. (AKLI) - S-1MEF SEC Filings 06/30/2021
Akili, Inc. (AKLI) - EFFECT SEC Filings 06/29/2021
Akili, Inc. (AKLI) - CERT SEC Filings 06/29/2021
Akili, Inc. (AKLI) - 8-A12B SEC Filings 06/29/2021
Akili, Inc. (AKLI) - S-1/A SEC Filings 06/25/2021
Akili, Inc. (AKLI) - CORRESP SEC Filings 06/25/2021
Akili, Inc. (AKLI) - UPLOAD SEC Filings 06/15/2021
Akili, Inc. (AKLI) - S-1/A SEC Filings 06/09/2021
Akili, Inc. (AKLI) - S-1 SEC Filings 06/02/2021
Akili, Inc. (AKLI) - DRS SEC Filings 04/21/2021

Press Releases

StockPrice Release
Akili reports first quarter 2024 financial results and provides business update 05/14/2024
Akili reports fourth quarter and full year 2023 financial results and provides business update 02/29/2024
Puretech founded entity akili announces positive results from shionogi's phase 3 clinical trial of localized version of akili's endeavorrx ® for pediatric adhd patients in japan 02/27/2024
Akili announces positive results from shionogi's phase 3 clinical trial of localized version of akili's endeavorrx® for pediatric adhd patients in japan 02/26/2024
Akili announces release date for fourth quarter and full year 2023 financial results, provides investor communications and board and corporate governance updates 02/21/2024
Akili to host third quarter financial results conference call and webcast on thursday, november 9 at 4:30 p.m. et 10/19/2023
Employees with adhd aren't reaching their full potential at work, akili study finds 10/12/2023
Akili announces leadership transition 10/06/2023
Akili releases endeavorotc™ on android™ devices, expanding treatment access for millions of adults with adhd 09/21/2023
Akili announces business transformation, focusing on non-prescription model 09/13/2023
Akili reports second quarter 2023 financial results and provides business update 08/10/2023
Akili to host second quarter financial results conference call and webcast on thursday, august 10 at 4:30 p.m. et 07/10/2023
Akili releases endeavorotctm video game treatment to improve attention in adults with adhd 06/07/2023
Akili to present clinical data from pivotal trial of video game treatment in adolescents with adhd at 2023 ascp annual meeting and elevate psych congress 05/31/2023
Akili reports first quarter 2023 financial results and provides business update 05/11/2023
Puretech founded entity akili announces adults with adhd see significant improvements in attention, adhd symptoms, and quality of life in clinical trial of akili's endeavorrx® video game-based therapeutic 05/04/2023
Puretech founded entity akili announces adults with adhd see significant improvements in attention, adhd symptoms, and quality of life in clinical trial of akili’s endeavorrx® video game-based therapeutic 05/04/2023
Adults with adhd see significant improvements in attention, adhd symptoms, and quality of life in clinical trial of akili’s endeavorrx® video game-based therapeutic 05/03/2023
Akili to host first quarter financial results conference call and webcast on thursday, may 11 at 4:30 p.m. et 04/13/2023
Akili reports fourth quarter and full year 2022 financial results and provides business update 03/07/2023
Akili to host fourth quarter and full year 2022 financial results conference call and webcast on tuesday, march 7 at 4:30 p.m. et 02/06/2023
Akili to participate in the cowen 43rd annual health care conference 02/02/2023
Akili to champion digital therapeutics in conjunction with j.p. morgan healthcare conference 01/06/2023
Pivotal trial of endeavorrxⓇ in adolescents with adhd shows robust improvements in attention and broader clinical outcomes 01/05/2023
Akili announces adhd expert dr. scott kollins to join as chief medical officer 12/01/2022
Akili reports third quarter 2022 financial results and company update 11/10/2022
Financial industry veteran mary hentges joins akili’s board of directors 10/27/2022
Akili to host third quarter 2022 financial results conference call and webcast on thursday, november 10 at 4:30 p.m. et 10/19/2022
Akili launches endeavorrx® expedition - a direct-to-patient product registry 09/21/2022
Akili to participate in lifesci partners healthtech symposium 09/19/2022
Digital medicine leader akili to list on nasdaq following successful business combination with social capital suvretta holdings corp. i 08/19/2022
Puretech founded entity akili announces public company board of director nominees 07/11/2022
Akili announces public company board of director nominees 07/11/2022
The american journal of psychiatry publishes data demonstrating akili interactive's digital therapeutic akl-t03 improves cognitive impairments in adults with major depressive disorder when combined with antidepressant medication 04/12/2022
Akili named to fast company's annual list of the world's 50 most innovative companies for 2022 03/08/2022
Akili to present at cowen's 42nd annual health care conference 03/07/2022
Akili to speak on integrating digital therapeutics into mainstream healthcare at dtx west 2022 02/18/2022
Plos one publishes clinical study results and eeg data showing akili digital therapeutic endeavorrx® activates systems in brain key to attentional functioning 02/17/2022
Puretech founded entity akili interactive announces filing of registration statement on s-4 in connection with its proposed business combination with social capital suvretta holdings corp. i 02/15/2022
Akili interactive announces filing of registration statement on s-4 in connection with its proposed business combination with social capital suvretta holdings corp. i 02/14/2022
Akili interactive, a leader in digital medicine, to become publicly traded through combination with social capital suvretta holdings corp. i 01/26/2022

More Headlines

News
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes. The company will not be hosting an earnings conference call for this release. Akili is also providing the following updates: Upcoming Conference Participation Akili CEO Matt Franklin wil. 02/21/2024
Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Akili, Inc. (AKLI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 01/15/2024
Akili, Inc. (AKLI) Upgraded to Buy: Here's What You Should Know Akili, Inc. (AKLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 12/21/2023
Akili, Inc. (AKLI) Q3 2023 Earnings Call Transcript Akili, Inc. (NASDAQ:AKLI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Caty Reid - Vice President Marketing & Communications Matt Franklin - President & Chief Operating Officer Scott Kollins - Chief Medical Officer Santosh Shanbhag - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Charles Rhyee - TD Cowen Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen and welcome to the Akili Interactive Labs Third Quarter 2023 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 9, 2023. 11/12/2023
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET BOSTON--(BUSINESS WIRE)--Akili to Host Third Quarter Financial Results Conference Call on Thursday, November 9 at 4:30 p.m. 10/19/2023
Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD. The study found that nearly all employees with ADHD (97%) think the. 10/12/2023
Akili Announces Leadership Transition BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement. 10/06/2023
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD. 09/21/2023
Akili Announces Business Transformation, Focusing on Non-prescription Model BOSTON--(BUSINESS WIRE)--Akili plans transition to non-Rx business, increasing patient access to clinically-proven non-drug treatments and reducing reliance on intermediaries. 09/13/2023
Akili, Inc. (AKLI) Q2 2023 Earnings Call Transcript Akili, Inc. (NASDAQ:AKLI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President, Communications Eddie Martucci - Chief Executive Officer Matt Franklin - President and Chief Operating Officer Santosh Shanbhag - Chief Financial Officer Scott Kollins - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Gus Paul - Morgan Stanley Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Akili, Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, August 10, 2023. 08/13/2023
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update. 08/10/2023
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An archived version of the webcast will be available on the company's website followi. 07/10/2023
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings. 05/31/2023
Why Is Akili (AKLI) Stock Up 21% Today? Akili (NASDAQ: AKLI ) stock is gaining on Wednesday after the company's video game treatment showed success in reducing ADHD in adults. Akili's EndeavorRx treatment uses video games to treat patients who deal with the effects of ADHD. 05/03/2023
Akili, Inc. (AKLI) Q4 2022 Earnings Call Transcript Akili, Inc. (NASDAQ:AKLI ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Scott Kollins - Chief Medical Officer Santosh Shanbhag - CFO & Treasurer Conference Call Participants Nicholas Japhet - Credit Suisse Michael Cherny - BofA Securities Rahul Rakhit - LifeSci Capital Vikram Purohit - Morgan Stanley Marie Thibault - BTIG Operator Greetings, and welcome to the Akili Fourth Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. 03/10/2023
5 Hot Penny Stocks Exploding After News This Week Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/05/2023
Akili, Inc. (AKLI) Q3 2022 Earnings Call Transcript Akili, Inc. (NASDAQ:AKLI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Joshua Young - IR Walter Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Santosh Shanbhag - CFO & Treasurer Conference Call Participants Charles Rhyee - Cowen Judah Frommer - Crédit Suisse Rahul Rakhit - LifeSci Capital Operator Greetings, and welcome to Akili's Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. 11/13/2022
Akili: Developing Video Games To Treat Cognitive Impairments Akili is developing video games as a means to treat ADHD, depression, and other conditions. The company has approval by the FDA to treat ADHD using its product EndeavorRx. It is also approved to market in "the European Economic Area." 10/31/2022
Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA) Akili announced it has completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (DNAA). These are the details. 08/20/2022
Akili to Present at Cowen's 42nd Annual Health Care Conference BOSTON--(BUSINESS WIRE)-- #DTx--Akili Management to Present at Cowen's 42nd Annual Health Care Conference 03/07/2022
DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger DNAA stock is on the rise today after news its blank-check company, backed by Chamath Palihapitiya, is merging with Akili Interactive. The post DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger appeared first on InvestorPlace. 01/26/2022
Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The SPAC Deal: Palihapitiya's Social Capital Suvretta Holdings Corp I (NASDAQ: DNAA) announced a SPAC merger with Akili Interactive, valuing the company at an equity value of $1 billion. 01/26/2022
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again? The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space. 01/09/2022

Unlock

AKLI Ratings Summary

AKLI Quant Ranking